PANCREATIC CANCER · White paper
Pancreatic Cancer Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About pancreatic cancer — and why its trials are hard
Pancreatic cancer, overwhelmingly ductal adenocarcinoma driven by KRAS, TP53 and CDKN2A mutations, is among the deadliest major cancers, with a five-year survival under 10% and frequent diagnosis at an advanced stage. It is the seventh-leading cause of cancer death worldwide (about 495,000 new cases in 2020). Only a minority of patients have resectable disease amenable to surgery (e.g., the Whipple procedure) plus adjuvant chemotherapy. For most, systemic chemotherapy is the mainstay: FOLFIRINOX (fluorouracil, leucovorin, irinotecan, oxaliplatin) for fit patients, or gemcitabine plus nab-paclitaxel (Abraxane). Second-line options include liposomal irinotecan (Onivyde) with 5-FU/leucovorin. Targeted and immuno-therapies help only defined subsets: olaparib for germline BRCA-mutated disease (POLO) and pembrolizumab for MSI-high/dMMR tumors. Development is notoriously difficult because dense desmoplastic stroma and poor tumor vascularization impede drug delivery, genetic heterogeneity limits targeted approaches, and late diagnosis with poor performance status shrinks the treatable, trial-eligible population, producing a long list of Phase 3 failures.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Nab-paclitaxel (Abraxane) | 2013 | First-line metastatic pancreatic adenocarcinoma, combined with gemcitabine | MPACT (NCT00844649) | Overall survival | Median OS 8.5 vs 6.7 months with gemcitabine alone (HR 0.72, p<0.0001); PFS 5.5 vs 3.7 months; ORR 23% vs 7% |
| Liposomal irinotecan (Onivyde) | 2015 | Metastatic disease after gemcitabine-based therapy, with 5-FU/leucovorin | NAPOLI-1 (NCT01494506) | Overall survival | Median OS 6.1 vs 4.2 months (HR 0.67-0.68, p~0.012-0.014); PFS 3.1 vs 1.5 months (no OS benefit for monotherapy) |
| Olaparib (Lynparza) | 2019 | First-line maintenance in germline BRCA-mutated metastatic disease after platinum response (PARP inhibitor) | POLO (NCT02184195) | Progression-free survival | Median PFS 7.4 vs 3.8 months vs placebo (HR 0.53, p=0.0035); no significant OS benefit at interim |
| Gemcitabine (Gemzar) | 1996 | First-line locally advanced or metastatic pancreatic cancer (historical backbone) | Pivotal Study 5 (NCT00003445) | Clinical benefit response and overall survival | Median OS ~5.7 vs 4.2 months vs 5-FU (p=0.0009); clinical benefit response 22-24% vs ~5% |
| Pembrolizumab (Keytruda) | 2017 | MSI-high / mismatch-repair-deficient unresectable or metastatic solid tumors, including pancreatic (tissue-agnostic; 2020 TMB-high) | KEYNOTE-158 / -164 (NCT02628067; program NCT02558894) | Objective response rate and duration of response | Durable responses (ORR ~34% in MSI-H cohorts) with median DOR exceeding 24 months in responders |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in pancreatic cancer development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| PEGPH20 (pegvorhyaluronidase alfa) — HALO-301 (NCT02715804) | Phase 3 failure; development halted | Stromal hyaluronan depletion did not improve overall survival, showing the difficulty of re-engineering the tumor microenvironment |
| Axitinib (VEGFR tyrosine kinase inhibitor) — NCT00545688 | Phase 3 halted | No survival improvement over gemcitabine, reflecting the failure of anti-angiogenic TKIs in this tumor |
| Demcizumab (anti-DLL4/Notch) — YOSEMITE (NCT02289898) | Failed Phase 2 | No significant survival effect, underscoring the complexity of targeting Notch signaling |
Choosing the right endpoint
Primary endpoints that matter in pancreatic cancer trials
- Overall survival (OS) — Definitive efficacy endpoint and the standard for approval, but demands large samples and long follow-up
- Progression-free survival (PFS) — Faster surrogate used for maintenance (e.g., POLO); hindered by variability in RECIST progression assessment
- Objective response rate (ORR) — Supports accelerated approval in defined subsets (e.g., MSI-H with pembrolizumab)
- Clinical benefit response — Composite of pain, performance status and weight; basis of gemcitabine's original palliative approval
- Biomarker response (CA 19-9) — Supports monitoring and target engagement, limited by assay/biology variability and need for validated biomarkers
How iNGENū runs pancreatic cancer trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
The full white paper: approved-product analyses, pivotal endpoints and trial-design strategy. Open-access · no sign-in.
Frequently asked questions
Pancreatic Cancer clinical trials — FAQs
What are the standard-of-care chemotherapy regimens for pancreatic cancer?
Do targeted or immunotherapies work in pancreatic cancer?
Why do so many pancreatic cancer drugs fail in clinical trials?
Ready to discuss your pancreatic cancer trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal